{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:48:26Z","timestamp":1754153306064,"version":"3.41.2"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1136\/ijgc-2020-001517","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T17:22:20Z","timestamp":1602696140000},"page":"1943-1950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Se Ik","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunhoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noh Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Sang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001517_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2020-001517_bb0015","unstructured":"N Howlader , AMNoone, MKrapcho, et al . SEER cancer statistics review, 1975-2016, National Cancer Institute. Available: https:\/\/seer.cancer.gov\/csr\/1975_2016\/ [Accessed 20 Dec 2020]."},{"key":"10.1136\/ijgc-2020-001517_bb0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2015.06.005","article-title":"Long-term mortality among women with epithelial ovarian cancer","volume":"138","author":"Dinkelspiel","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PLoS Med"},{"key":"10.1136\/ijgc-2020-001517_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2015.11.001","article-title":"Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer","volume":"53","author":"Lambrechts","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001517_bb0035","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001517_bb0040","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0045","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0050","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0060","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0065","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/IGC.0b013e31829f17c9","article-title":"Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer","volume":"23","author":"Rauh-Hain","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001517_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.05.017","article-title":"Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: a case-control study","volume":"142","author":"Petrillo","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2013.04.055","article-title":"Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers","volume":"130","author":"Dao","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jjco\/hyy175","article-title":"Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys","volume":"49","author":"Park","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001517_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1136\/ijgc-2020-001517_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.coc.0000258119.90805.ca","article-title":"Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging","volume":"30","author":"Koukourakis","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0100","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-09-0731","article-title":"Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001517_bb0105","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091967","article-title":"Biological pathways involved in tumor angiogenesis and bevacizumab based anti-angiogenic therapy with special references to ovarian cancer","volume":"18","author":"Loizzi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ijgc-2020-001517_bb0115","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1136\/ijgc-2020-001517_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of ago desktop III\/ENGOT-ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0130","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001517_bb0135","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001517_bb0140","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1136\/ijgc-2020-001517_bb0145","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1067\/mob.2000.107092","article-title":"Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor","volume":"183","author":"Gossmann","year":"2000","journal-title":"Am J Obstet Gynecol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24012428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24012428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:19:48Z","timestamp":1753222788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24012428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1048891X24012428"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001517","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}